Summary
Acetaminophen has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Multiple Myeloma would be drug repurposing rather than first-in-human development. This does not mean it is approved for Multiple Myeloma. ClinicalTrials.gov lists 8 registered trials linking Acetaminophen to Multiple Myeloma: 1 is currently recruiting; 2 are active or not yet recruiting; 1 has completed; 4 are terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 4 (NCT07101445). The largest enrolment is 337 participants (NCT04270409). Registration activity spans 2005 to 2025. No published literature item is linked to Acetaminophen and Multiple Myeloma in the OSMF database yet, so the record rests on registry entries alone. Registry entries describe intent to study, not outcomes.
The RepurpOS disease-intelligence file for Multiple Myeloma ranks 50 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: Essentially zero; MGUS (precursor) progresses to myeloma in 1%/year; median survival without treatment <1 year once symptomatic.
Evidence table
| Evidence tier | A · Strong |
|---|---|
| Evidence score | 42.5 (trials 22.5, literature 0.0, tier 15, approved bonus 5.0) |
| Registered trials | 8 total: 1 recruiting, 2 active / not yet recruiting, 1 completed, 4 other |
| Linked publications | 0 |
| Agent type | Drug (Small molecule) |
| Development stage (any indication) | Approved |
| Mechanism / class | Not recorded |
| Data sources | DGIdb |
| Linked via biomarker / target | CCND1 |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
| NCT ID | Title | Status | Phase | Enrolment |
|---|---|---|---|---|
| NCT07101445 | Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial 2025 | recruiting | Phase 4 | 94 |
| NCT04270409 | Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma 2020 | active, not recruiting | Phase 3 | 337 |
| NCT04268498 | A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma 2020 | active, not recruiting | Phase 2 | 310 |
| NCT02661035 | Allo HSCT Using RIC for Hematological Diseases 2017 | completed | Phase 2 | 156 |
| NCT05298683 | A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor 2022 | status unknown | Phase 2 | 108 |
| NCT01846429 | Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain 2013 | terminated | Phase 1 | 9 |
| NCT00176475 | Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease 2005 | terminated | Phase 1 | 2 |
| NCT02541643 | Expanded Access Single Named Patient Program With Elotuzumab (BMS-901608) for the Treatment of Patient R-A With Relapsed/Refractory Multiple Myeloma | no_longer_available | Not applicable | — |
Published literature
No publication is linked to this pair yet.
Mechanism and notes
No mechanism of action is recorded for this pair in the source databases.
OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target CCND1. The tier describes how well the drug-disease link is documented, not how well the drug works.
Frequently asked questions
Is Acetaminophen approved for Multiple Myeloma?
Acetaminophen has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Multiple Myeloma would be drug repurposing rather than first-in-human development. This does not mean it is approved for Multiple Myeloma. Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Acetaminophen in clinical trials for Multiple Myeloma?
ClinicalTrials.gov lists 8 registered trials linking Acetaminophen to Multiple Myeloma: 1 is currently recruiting; 2 are active or not yet recruiting; 1 has completed; 4 are terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 4 (NCT07101445). The largest enrolment is 337 participants (NCT04270409). Registration activity spans 2005 to 2025.
What does the evidence show for Acetaminophen in Multiple Myeloma?
Acetaminophen has 1 completed registered trial for Multiple Myeloma but no linked publication, which usually means results are unpublished, pending, or not yet matched to this record. OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target CCND1. The tier describes how well the drug-disease link is documented, not how well the drug works.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-06. Page built 2026-10-07.